Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines
-
- Ma Chaoya
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
-
- Horlad Hasita
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
-
- Pan Cheng
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
-
- Yano Hiromu
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
-
- Ohnishi Koji
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
-
- Fujiwara Yukio
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
-
- Matsuoka Masao
- Department of Hematology, Graduate School of Medical Sciences, Kumamoto University Laboratory of Virus Control, Institute for Virus Research, Kyoto University
-
- Lee Aeju
- International Research Organization for Advanced Science and Technology (IROAST), Kumamoto University Magnesium Research Center, Kumamoto University
-
- Niidome Takuro
- Faculty of Advanced Science and Technology, Kumamoto University
-
- Yamanaka Ryuya
- Kyoto Prefectural University of Medicine, Graduate School for Health Care Science
-
- Takeya Motohiro
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
-
- Komohara Yoshihiro
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
Search this article
Abstract
<p>Recent studies have indicated the significance of immune checkpoint molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell immunoglobulin and mucin domain-containing molecule-3 for anti-tumor immune responses. We previously investigated PD-1 ligand 1/2 (PD-L1/2) expression in lymphoma cell lines, and found that PD-L1/2 is expressed on the adult T-cell leukemia/lymphoma (ATL-T) and B-cell lymphoma (SLVL) cell lines. In the present study, we investigated whether the Stat3 inhibitor WP1066 abrogated PD-L1/2 expression in lymphoma cell lines. Incubation with WP1066 inhibited lymphoma cell growth and induced cell apoptosis. PD-L1/2 expression in the ATL-T, SLVL, and human brain malignant lymphoma (HKBML) cell lines was significantly abrogated by WP1066 treatment. These data indicated that a Stat3 inhibitor abrogated PD-L1/2 expression in lymphoma cells. Such an inhibitor is therefore considered to be useful for additional immunotherapy in patients with advanced lymphoma.</p>
Journal
-
- Journal of Clinical and Experimental Hematopathology
-
Journal of Clinical and Experimental Hematopathology 57 (1), 21-25, 2017
The Japanese Society for Lymphoreticular Tissue Research